Headquarters
USA
Every company in the roster headquartered in USA.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
165 of 165 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 Halia TherapeuticsPrivate | 1 asset: 1 Ph 2 | HT-4253Phase 2 · Alzheimer's Disease | Feb 2028HT-4253 · Phase 2 |
 HeartWorksPrivate | 1 asset: 1 Ph 1 | iPSC-CLPhase 1 · Heart Failure | Sep 2027iPSC-CL · Phase 1 |
 Humanetics CorporationPrivate | 1 asset: 1 Ph 2 | BIO 300Phase 2 · Non-Small Cell Lung CancerWeak signal | None on record |
 INmune BioINMB · Nasdaq | 1 asset: 1 Ph 2 | XPro1595Phase 2 · Alzheimer's DiseasePartial signal | None on record |
 Imbria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NinerafaxstatPhase 2 · Heart FailureWeak signal | Dec 2026Ninerafaxstat · Phase 2 |
 IntralytixPrivate | 1 asset: 1 Ph 2 | EcoActivePhase 1/2 · Crohn's Disease | None on record |
 Jasper Therapeutics, Inc.JSPR · Nasdaq | 1 asset: 1 Ph 2 | BriquilimabPhase 2 · AsthmaPartial signal | None on record |
 Jina PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | nanosomal tacrolimusPhase 2 · Ulcerative Colitis | None on record |
 KallyopePrivate | 1 asset: 1 Ph 3 | ElismetrepPhase 3 · Migraine | Feb 2027Elismetrep · Phase 3 |
 Kestrel TherapeuticsPrivate | 1 asset: 1 Ph 1 | KST-6051Phase 1 · Non-Small Cell Lung Cancer | Jun 2027KST-6051 · Phase 1 |
 Kinaset TherapeuticsPrivate | 1 asset: 1 Ph 2 | frevecitinibPhase 2 · Chronic Obstructive Pulmonary DiseasePartial signal | 30 Nov 2027frevecitinib · Phase 2 |
 LAPIX TherapeuticsPrivate | 1 asset: 1 Ph 1 | LPX-TI641Phase 1 · Psoriatic Arthritis | None on record |
 Lexeo TherapeuticsLXEO · Nasdaq | 1 asset: 1 Ph 2 | LX1001Phase 1/2 · Alzheimer's DiseaseWeak signal | Nov 2028LX1001 · Phase 1 |
Libella Gene TherapeuticsPrivate | 1 asset: 1 Ph 1 | AAV-hTERTPhase 1 · Alzheimer's DiseaseWeak signal | None on record |
 Lighthouse PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | LHP588Phase 2 · Alzheimer's Disease | 31 Jan 2029LHP588 · Phase 2 |
 Lisata TherapeuticsLSTA · Nasdaq | 1 asset: 1 Ph 2 | certepetidePhase 2 · Pancreatic Cancer | None on record |
 Longeveron (NASDAQ: LGVN)LGVN · Nasdaq | 1 asset: 1 Ph 2 | LaromestrocelPhase 2 · Alzheimer's DiseasePartial signal | None on record |
 MTI Biotech Inc.Private | 1 asset: 1 Ph 2 | 2-hydroxybenzylamine acetatePhase 1/2 · Alzheimer's Disease | 30 Dec 20282-hydroxybenzylamine acetate · Phase 1/2 |
 MapLight TherapeuticsMPLT · Nasdaq | 1 asset: 1 Ph 2 | ML-007C-MAPhase 2 · SchizophreniaPartial signal | Dec 2027ML-007C-MA · Phase 2 |
 Mineralys TherapeuticsMLYS · Nasdaq | 1 asset: 1 Ph 3 | LorundrostatPhase 3 · HypertensionReliable signal | None on record |
 NGM BiopharmaceuticalsPrivate | 1 asset: 1 Ph 2 | NGM707Phase 1/2 · Non-Small Cell Lung CancerWeak signal | None on record |
 NKGen BiotechNKGN · OTC | 1 asset: 1 Ph 2 | SNK01Phase 1/2 · Alzheimer's DiseaseWeak signal | Mar 2028SNK01 · Phase 1/2 |
 NSC-TherapeuticsPrivate | 1 asset: 1 Ph 2 | NSC001Phase 1/2 · Alzheimer's Disease | None on record |
| 1 asset: 1 Ph 2 | TraneurocinPhase 2 · Alzheimer's DiseasePartial signal | None on record | |
 NeuroPro Therapeutics, Inc.Private | 1 asset: 1 Ph 2 | NPT2042Phase 2 · EpilepsyPartial signal | None on record |
 NeuroTherapia, Inc.Private | 1 asset: 1 Ph 2 | NTRX-07Phase 2 · Alzheimer's DiseasePartial signal | None on record |
 Neuronascent, Inc.Private | 1 asset: 1 Ph 1 | NNI-362Phase 1 · Alzheimer's DiseasePartial signal | None on record |
 Odyssey TherapeuticsPrivate | 1 asset: 1 Ph 2 | OD-07656Phase 2 · Ulcerative ColitisWeak signal | None on record |
 Oligomerix, IncPrivate | 1 asset: 1 Ph 1 | OLX-07010Phase 1 · Alzheimer's Disease | None on record |
 Palisade BioPALI · Nasdaq | 1 asset: 1 Ph 2 | PALI-2108Phase 2 · Ulcerative ColitisPartial signal | Oct 2027PALI-2108 · Phase 2 |
 PharmatrophiXPrivate | 1 asset: 1 Ph 2 | LM11A-31Phase 1/2 · Alzheimer's DiseasePartial signal | None on record |
 PulmatrixPULM · Nasdaq | 1 asset: 1 Ph 2 | PUR1900Phase 2 · Allergic Bronchopulmonary Aspergillosis | None on record |
 PulmovantPrivate | 1 asset: 1 Ph 3 | MosliciguatPhase 3 · Pulmonary Hypertension | Dec 2026Mosliciguat · Phase 2 |
 Quince TherapeuticsQNCX · Nasdaq | 1 asset: 1 Ph 2 | LAM-001Phase 2 · Bronchiolitis Obliterans Syndrome | Mar 2028LAM-001 · Phase 2 |
 ReAlta Life SciencesPrivate | 1 asset: 1 Ph 2 | RLS-0071Phase 2 · Chronic Obstructive Pulmonary Disease | Dec 2026RLS-0071 · Phase 2 |
| 1 asset: 1 Ph 2 | RB-ADSCPhase 2 · Alzheimer's Disease | Sep 2028RB-ADSC · Phase 1 | |
 Retension PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | RTN-001Phase 2 · Hypertension | Mar 2027RTN-001 · Phase 2 |
 Rise TherapeuticsPrivate | 1 asset: 1 Ph 1 | R-3750Phase 1 · Ulcerative Colitis | 30 Apr 2028R-3750 · Phase 1 |
River 2 RenalPrivate | 1 asset: 1 Ph 2 | R2R01Phase 2 · Heart FailurePartial signal | 1 Apr 2027R2R01 · Phase 2 |
 Rivus PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | HU6Phase 2 · Heart FailurePartial signal | Feb 2027HU6 · Phase 2 |
 Sagimet Biosciences Inc.SGMT · Nasdaq | 1 asset: 1 Ph 3 | DenifanstatPhase 3 · MASH / NASHReliable signal | None on record |
 Sardocor (Medera Biopharma)Private | 1 asset: 1 Ph 2 | AAV1.SERCA2aPhase 1/2 · Heart Failure | Oct 2027AAV1.SERCA2a · Phase 1 |
 Sarfez PharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
SatRxPrivate | 1 asset: 1 Ph 3 | GosogliptinPhase 3 · Type 2 DiabetesPartial signal | None on record |
 Scholar RockSRRK · Nasdaq | 1 asset: 1 Ph 3 | apitegromabPhase 3 · Spinal Muscular AtrophyPartial signal | 1 Nov 2026apitegromab · Phase 3 |
Scilex BioPrivate | 1 asset: 1 Ph 2 | KDS2010Phase 2 · Alzheimer's Disease | 31 Jan 2027KDS2010 · Phase 2 |
 Secretome TherapeuticsPrivate | 1 asset: 1 Ph 1 | STM01Phase 1 · Heart Failure | None on record |
 Seismic TherapeuticPrivate | 1 asset: 1 Ph 1 | S-4321Phase 1 · Psoriatic Arthritis | Sep 2027S-4321 · Phase 1 |
 Skye BioscienceSKYE · Nasdaq | 1 asset: 1 Ph 2 | nimacimabPhase 2 · Obesity | 20 Nov 2026nimacimab · Phase 2 |
 Sorriso PharmaceuticalsPrivate | 1 asset: 1 Ph 1 | SOR102Phase 1 · Ulcerative ColitisPartial signal | None on record |
 Sparrow PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | clofutribenPhase 2 · Type 2 DiabetesWeak signal | 31 Dec 2027clofutriben · Phase 2 |
 SpinogenixPrivate | 1 asset: 1 Ph 2 | SPG302Phase 2 · Alzheimer's Disease | 31 Dec 2027SPG302 · Phase 2/3 |
 Structure TherapeuticsGPCR · Nasdaq | 1 asset: 1 Ph 3 | aleniglipronPhase 3 · ObesityPartial signal | Sep 2028aleniglipron · Phase 3 |
 T3D TherapeuticsPrivate | 1 asset: 1 Ph 3 | T3D-959Phase 2/3 · Alzheimer's DiseasePartial signal | Apr 2031T3D-959 · Phase 2/3 |
 Tectonic TherapeuticTECX · Nasdaq | 1 asset: 1 Ph 2 | Fc-relaxin fusion protein (TX45)Phase 2 · Hypertension | 24 Nov 2026Fc-relaxin fusion protein (TX45) · Phase 2 |
 Tenax TherapeuticsTENX · Nasdaq | 1 asset: 1 Ph 3 | LevosimendanPhase 3 · Heart FailurePartial signal | 30 Jun 2028Levosimendan · Phase 3 |
 Therini Bio, Inc.Private | 1 asset: 1 Ph 1 | THN391Phase 1 · Alzheimer's Disease | 31 Mar 2027THN391 · Phase 1 |
 Upstream BioUPB · Nasdaq | 1 asset: 1 Ph 2 | verekitugPhase 2 · Chronic Obstructive Pulmonary DiseaseReliable signal | Sep 2027verekitug · Phase 2 |
 Vaccinex, Inc.VCNX · OTC | 1 asset: 1 Ph 2 | PepinemabPhase 1/2 · Alzheimer's DiseasePartial signal | 31 Dec 2028Pepinemab · Phase 1/2 |
 Vantive HealthPrivate | 1 asset: 1 approved | Approved assets only | None on record |
 Vasa TherapeuticsPrivate | 1 asset: 1 Ph 1 | Vasa Therapeutics VS-041Phase 1 · Heart Failure | None on record |
 VentrixPrivate | 1 asset: 1 Ph 1 | VentriGelPhase 1 · Heart FailureWeak signal | None on record |
Virogenics, Inc.Private | 1 asset: 1 Ph 1 | CMS121Phase 1 · Alzheimer's DiseasePartial signal | None on record |
Zomagen BiosciencesPrivate | 1 asset: 1 Ph 2 | VTX3232Phase 2 · ObesityPartial signal | None on record |
 scPharmaceuticalsPrivate | 1 asset: 1 approved | Approved assets only | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).